# Table of Contents

**Foreword** ................................................................. xiii  
  
**Acknowledgments** ..................................................... xv  
  
**Contributors** ........................................................... xvii  
  
**Chapter 1**  Regulatory and Scientific Strategies for Preclinical Safety  
  Program Design, and the Importance of Subchronic Toxicity Testing  
  ................................................................. 3  
  
*Richard Schwen*  
  
General Considerations in the Design of Preclinical Safety Programs ............... 4  
Preclinical Program Design: The Steps and Examples .................................... 6  
The Key Role of Subchronic Toxicity Studies .............................................. 9  
  
**Chapter 2**  Scientific and Regulatory Aspects of Nonclinical Drug Development to Meet European Requirements  
  ................................................................. 11  
  
*David Snodin*  
  
Europe: Geopolitical Factors .................................................. 11  
Drug Regulatory Framework in the European Union .................................... 15  
Nonclinical Drug Development in Europe ............................................... 28  
Concluding Comments ................................................................... 36  
  
**Chapter 3**  Risk Assessment for Chemical Exposure  
  ................................................................. 41  
  
*Robert C. Bookstaff, Steven H. Robison and Richard Schwen*  
  
Hazard Identification ...................................................... 43  
Exposure and Dose-Response Assessment ............................................. 48  
Risk Characterization .................................................................. 57  
Applications of Drug Safety Assessment ............................................. 58  
  
**Chapter 4**  Practical Considerations for Conduct of Preclinical Programs  
  ................................................................. 63  
  
*Sharon Buring Stuard*  
  
Protocols, Text Articles and Lab Selection ........................................... 63  
Good Laboratory Practice and Study Monitoring .................................... 68
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Single-Dose Toxicology Studies</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td>David Virgo</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Classic Acute Testing</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td>Single-Dose Tests for Phase 1</td>
<td>83</td>
</tr>
<tr>
<td>6</td>
<td>Cardiovascular Safety Pharmacology</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Nick McMahon, Chris Pollard, Tim Hammond and Jean-Pierre Valentin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regulatory Requirements</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>General Considerations and Principles</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>Core Battery and Follow-up Studies</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Follow-up Studies</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Predictive Value for Humans of Nonclinical Cardiovascular Safety Pharmacology Testing</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>Current and Future Challenges</td>
<td>114</td>
</tr>
<tr>
<td></td>
<td>Conclusion</td>
<td>116</td>
</tr>
<tr>
<td></td>
<td>Acknowledgments</td>
<td>117</td>
</tr>
<tr>
<td>7</td>
<td>Respiratory Safety Pharmacology</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>Wherly Hoffman, Mary Jeanne Kallman and Mario Sgro</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Protocol Elements for the Study Design</td>
<td>126</td>
</tr>
<tr>
<td></td>
<td>Statistical Analysis</td>
<td>130</td>
</tr>
<tr>
<td></td>
<td>Reporting and Interpretation</td>
<td>131</td>
</tr>
<tr>
<td></td>
<td>Summary of Current Issues and Future Directions</td>
<td>134</td>
</tr>
<tr>
<td></td>
<td>Acknowledgment</td>
<td>135</td>
</tr>
<tr>
<td>8</td>
<td>CNS Safety Pharmacology</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td>Roger D. Porsolt, Niklaus Dürm Müller, Vincent Castegné and Paul Moser</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Core Battery CNS Safety Pharmacology Procedures</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td>Follow-up CNS Safety Pharmacology Procedures</td>
<td>146</td>
</tr>
<tr>
<td></td>
<td>Electroencephalograph Studies</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td>Drug Abuse and Dependence</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>General Conclusions</td>
<td>160</td>
</tr>
<tr>
<td>9</td>
<td>Reproductive and Developmental Toxicology</td>
<td>163</td>
</tr>
<tr>
<td></td>
<td>Thomas F.X. Collins and Robert L. Sprando</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction and Historical Perspective</td>
<td>163</td>
</tr>
<tr>
<td></td>
<td>General Considerations for Studies</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>Endpoints of Possible Toxicity</td>
<td>175</td>
</tr>
</tbody>
</table>
Table of Contents

Chapter 10  Genotoxicity Testing and Risk Management  .................................................. 197
   Peggy Guzzie-Peck

   Classes of Genotoxic Damage ................................................................. 197
   Consequences of Genotoxic Damage: Location, Location, Location... .... 199
   Indirect Effects on DNA, Chromosomes and Gene Expression .............. 203
   Costs and Benefits in Early Hazard Identification ................................. 205
   Impact of Genotoxicity on Drug Labeling .............................................. 206
   The ICH Core Battery ........................................................................... 208
   In Vitro Tests for Genotoxicity ............................................................... 210
   General Consideration for In Vitro Tests .............................................. 211
   Test-Specific Methodology for In Vitro Tests ...................................... 216
   Mammalian Mutation Assays ................................................................. 220
   Critical Components of Mutation Assays ............................................. 223
   Interpretation of Mutation Responses ................................................... 226
   Interpretation of Mammalian Mutation Data ....................................... 228
   Testing for In Vitro Chromosomal Changes ................................ ...... 230
   Interpretation and Significance of Numerical Changes ...................... 236
   In Vitro Micronucleus Test ................................................................... 238
   Integrating Data from Multiple Studies: Weight-of-Evidence Approach . 242
   In Vivo Tests for Genotoxicity ............................................................... 244
   Evaluation of In Vivo Test Results ......................................................... 249
   Genotoxicity Risk Management ............................................................. 250
   DNA Damage Assays ........................................................................... 252
   Other Assays to Assess the Mechanism or Relevance of In Vitro Findings . 257
   Thresholds and Follow-up Testing in Genotoxicity Risk Management .... 262
   Assessing the Risks and the Costs Versus Benefits ............................ 265
   Triggers for Additional Needs for Genotoxicity Testing ....................... 266

Chapter 11  Carcinogenicity Studies in Support of Drug Approval ................. 273
   Abigail Jacobs

   When Are Carcinogenicity Studies Needed During Drug Development? .... 273
   Protocol Design for a Traditional Two-Year Carcinogenicity Study .......... 274
   Interpretation of Results ................................................................. 278

Chapter 12  Role of Toxicokinetics and Drug Metabolism in Nonclinical Toxicology Testing ... 289
   Jayesh Vora and Pankaj Desai

   A Motivating Example ................................................................. 289
   Study Design Considerations ............................................................. 290
   Data Analysis and Interpretation ......................................................... 294
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Special Considerations in the Preclinical Testing of Biologics: The ICH S6 Guideline</td>
</tr>
<tr>
<td>14</td>
<td>Toxicity Testing of Vaccines</td>
</tr>
<tr>
<td>15</td>
<td>Biosafety and Nonclinical Assessments of Cell- and Tissue-Based Products in the United States</td>
</tr>
<tr>
<td>16</td>
<td>Inhalation Toxicology</td>
</tr>
</tbody>
</table>

### Chapter 13: Special Considerations in the Preclinical Testing of Biologics: The ICH S6 Guideline

**Peter R. Ryle**

- Introduction ........................................... 301
- Differences Between Biologics and Small Molecule Drugs ........... 305
- Regulatory Guidance ..................................... 306
- Special Considerations .................................. 313
- Concluding Remarks ..................................... 327

### Chapter 14: Toxicity Testing of Vaccines

**Polly Y. Chang, Joan Roelands, Janice Schindler-Horvat, and Rebecca L. Sheets**

- Brief Overview of Vaccine Manufacture ...................... 334
- Preclinical In Vivo Toxicity Testing of Vaccines .......... 335
- Summary ................................................. 342

### Chapter 15: Biosafety and Nonclinical Assessments of Cell- and Tissue-Based Products in the United States

**Darin J. Weber and David J. Pepperl**

- Introduction ........................................... 345
- The Regulatory Framework for Cell- and Tissue-Based Products .... 346
- Biosafety Considerations for Sources of Cells and Ancillary Materials 347
- The Manufacturing Process and the Product .................. 349
- Nonclinical Studies of Cell- and Tissue-Based Products ........ 349
- Nonclinical Studies in Support of Cell and Tissue Therapies .... 353
- Examples of Nonclinical Programs for Cell and Tissue Products ... 362
- Outsourcing Nonclinical Studies of Cell- and Tissue-Based Products 368
- The Future of Cell- and Tissue-Based Product Regulation ........ 370

### Chapter 16: Inhalation Toxicology

**Ron Wolff, Heather Persson, Guy Lalonde, Shawn Melton, Kimberly Perkins, Juergen W. Pfeiffer, Theresa Sweeney, Simon Rothenberg and Brian Vuillemenot**

- Introduction ........................................... 373
- Regulations and Guidances ................................ 374
- Inhalation Exposure Systems ................................ 374
- Design Considerations for Inhalation Repeat-Dose Studies ....... 382
- Dose ...................................................... 383
- Specific Endpoints for Inhalation Studies .................... 387
- Conduct of Inhalation Studies Using Contract Research Organizations 391
- Summary ................................................. 392
Developmental Neurotoxicity Evaluations ................................. 469
Interpretation of Behavioral Endpoints ................................. 469

Chapter 21  Toxicological Considerations for Further Development of Marketed Drugs  . 477
Paul Baldrick
Toxicological Considerations for Line Extensions ............................ 478
Toxicological Considerations for Combination Products .......................... 486
Toxicological Considerations for Generics and Biosimilars .......................... 487
Challenges and the Future .................................................................. 489

Chapter 22  Genetic Polymorphisms and Their Impact on Drug Safety and Efficacy Profiles ........................................... 493
Steve Boesing
Metabolic Pathways: Cytochrome P450 and Polymorphisms .................. 493
Metabolic Pathway Determination .................................................... 499
Pharmacogenetics and Polymorphisms: Nonmetabolic Pathways ................. 502
Early Assessment of Genetic Polymorphism Impacts:
  Applicability to FDA Guidance ....................................................... 504
Conclusion ..................................................................................... 505

Chapter 23  Evaluation of Nephrotoxicity of Bisphosphonates ..................... 509
Thomas Pfister
Bisphosphonates ........................................................................ 509
Standard General Toxicity Studies .................................................. 510
Nonclinical Testing Strategy for Nephrotoxicity .................................... 511
Designs and Results of Nonclinical Renal Safety Studies .......................... 512
Discussion and Conclusion ............................................................... 533

Chapter 24  Ranolazine: Nonclinical Safety Pharmacology Studies
Supporting Regulatory Approval ....................................................... 539
Jean-Pierre Valentin, Najah Abi-Gerges and Tim Hammond
Clinical Effects of Ranolazine on Cardiac Repolarization ..................... 540
Nonclinical Effects of Ranolazine on Cardiac Repolarization .................... 542
Integrated Risk Assessment for Ranolazine ......................................... 549
Conclusion ..................................................................................... 551

Chapter 25  Environmental Safety Assessment of Drugs: Case Study for Alesse .............. 557
Laurie J. Carpenter
Format for an Environmental Assessment ........................................... 558
Environmental Issues .................................................................. 561
Physical Chemistry Data .................................................................. 562
Depletion .........................................................................................
Table of Contents

Chapter 26  Toxicology Assessment of Fluoroquinolones: A Case Study  571
  Kazuhisa Furuhama
  QT Prolongation  571
  Convulsions  577
  Phototoxicity  578
  Chondrotoxicity  580
  Hepatotoxicity  581
  Miscellaneous Toxicities  582

Glossary  589

Index  599